Home › Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration
 

Keywords :   


Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration

2016-04-15 03:46:09| drugdiscoveryonline Home Page

Transplant Genomics Inc. ("TGI") and Quark Pharmaceuticals, Inc. ("Quark") today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI's TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with Quark's proprietary drug candidate QPI-1002.

Tags: development collaboration discovery announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
16.05Eastern North Pacific Tropical Weather Outlook
16.05Amherst Label adds third Domino press
16.05Atlantic Tropical Weather Outlook
16.05Simply.TV provides metadata to Drei TV Austria
16.05Backlash as Morrisons trials sale of New Zealand lamb
More »